17:05 , Aug 23, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers A three-protein signature in tumor-infiltrating lymphocytes (TILs) could help predict response to PD-1 and PD-L1 inhibitors in NSCLC. In pre-treatment tumor samples from 39 NSCLC patients treated with PD-1 or PD-L1 inhibitors,...
23:27 , Jun 14, 2018 |  BC Innovations  |  Tools & Techniques

Imaging immunotherapy

Stanford University researchers have made an imaging agent that detects activated T cells and could predict whether a patient will respond to immunotherapy within days of treatment. Typically, it takes weeks to months to determine...
21:36 , May 30, 2018 |  BC Extra  |  Preclinical News

Tet2 disruption improves Kymriah efficacy

In a...
19:06 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest inhibiting CHI3L1 could help treat lung metastases of melanoma. In mouse melanoma cells co-cultured with mouse CD8 + T cells, CHI3L1 knockout in the T cells increased...
23:39 , Oct 27, 2017 |  BC Extra  |  Preclinical News

Cell study points to new antibiotic strategy

A study in...
18:41 , Aug 9, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cervical cancer; breast cancer Patient sample, cell culture and mouse studies suggest inhibiting HDAC1 alone or in combination with T cell therapies could help treat NANOG -positive cervical and breast cancers. In cervical cancer...
08:00 , Feb 18, 2016 |  BC Innovations  |  Targets & Mechanisms

Staking out foxholes

A pair of studies from a Memorial Sloan Kettering Cancer Center (MSKCC) lab has uncovered two new handles for tuning the immune system to fight solid tumors. By focusing on processes that regulate immune suppression...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

viDA Therapeutics, Centre for Drug Research and Development deal

The center and viDA partnered to develop VTI-1002 to treat discoid lupus erythematosus (DLE). The partners will develop a clinical-grade formulation of the preclinical topical small molecule granzyme B (GrB; GZMB ) inhibitor to support...
07:00 , Oct 29, 2015 |  BC Innovations  |  Translation in Brief

Tumor turncoat

Instead of engineering T cells to kill tumors, researchers at The Scripps Research Institute have found a way to direct a patient's own leukemia cells to kill each other by using an agonist antibody that...
07:00 , May 29, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Transplantation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Transplantation Bone marrow transplant (BMT) Granzyme B (GrB; GZMB) Mouse studies suggest inhibiting GZMB could help improve bone marrow reconstitution following hematopoietic stem cell (HSC) transplantation....